A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
Hereditary hemochromatosis (HH) is characterized by increased intestinal iron absorption that may result in iron overload. Although phlebotomy is widely practiced, it is poorly tolerated or contraindicated in patients with anemias, severe heart disease, or poor venous access, and compliance can vary. The once-daily, oral iron chelator, deferasirox (Exjade) may provide an alternative treatment option. Patients with HH carrying the HFE gene who were homozygous for the Cys282Tyr mutation, serum ferritin levels of 300-2000 ng/mL, transferrin saturation ≥ 45%, and no known history of cirrhosis were enrolled in this dose-escalation study to characterize the safety and efficacy of deferasirox, comprising a core and an extension phase (each 24 weeks). Forty-nine patients were enrolled and received starting deferasirox doses of 5 (n = 11), 10 (n = 15), or 15 (n = 23) mg/kg/day. Adverse events were generally dose-dependent, the most common being diarrhea, headache, and nausea (n = 18, n = 10, and n = 8 in the core and n = 1, n = 1, and n = 0 in the extension, respectively). More patients in the 15 mg/kg/day than in the 5 or 10 mg/kg/day cohorts experienced increases in alanine aminotransferase and serum creatinine levels during the 48-week treatment period; six patients had alanine aminotransferase > 3 × baseline and greater than the upper limit of normal range, and eight patients had serum creatinine > 33% above baseline and greater than upper limit of normal on two consecutive occasions. After receiving deferasirox for 48 weeks, median serum ferritin levels decreased by 63.5%, 74.8%, and 74.1% in the 5, 10, and 15 mg/kg/day cohorts, respectively. In all cohorts, median serum ferritin decreased to < 250 ng/mL.


CONCLUSIONS
Deferasirox doses of 5, 10, and 15 mg/kg/day can reduce iron burden in patients with HH. Based on the safety and efficacy results, starting deferasirox at 10 mg/kg/day appears to be most appropriate for further study in this patient population.
Phatak
Pradyumna
P
Rochester General Hospital, Rochester, NY, USA. Prad.Phatak@rochestergeneral.org
Brissot
Pierre
P
Wurster
Mark
M
Adams
Paul C
PC
Bonkovsky
Herbert L
HL
Gross
John
J
Malfertheiner
Peter
P
McLaren
Gordon D
GD
Niederau
Claus
C
Piperno
Alberto
A
Powell
Lawrie W
LW
Russo
Mark W
MW
Stoelzel
Ulrich
U
Stremmel
Wolfgang
W
Griffel
Louis
L
Lynch
Nicola
N
Zhang
Yiyun
Y
Pietrangelo
Antonello
A
D000328:Adult; D000368:Aged; D019943:Amino Acid Substitution; D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D000077588:Deferasirox; D004305:Dose-Response Relationship, Drug; D005260:Female; D005293:Ferritins / Q000097:blood / Q000235:genetics; D006432:Hemochromatosis / Q000097:blood / Q000150:complications* / Q000235:genetics / Q000628:therapy; D006720:Homozygote; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019190:Iron Overload / Q000097:blood / Q000188:drug therapy* / Q000209:etiology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018962:Phlebotomy / Q000379:methods; D012449:Safety; D014168:Transferrin / Q000378:metabolism; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
D001565:Benzoates; D007502:Iron Chelating Agents; D014168:Transferrin; D014230:Triazoles; D005293:Ferritins; D003404:Creatinine; D000077588:Deferasirox
Am J Hematol. 2006 Mar;81(3):225-6
16493613
Haematologica. 2006 Oct;91(10):1343-51
17018383
Am J Gastroenterol. 2003 Sep;98(9):2072-7
14499790
Can J Cardiol. 1997 Apr;13(4):391-4
9141972
Br J Haematol. 2007 Feb;136(3):501-8
17233848
Gastroenterology. 2008 Dec;135(6):1945-52
18848943
Lancet. 2002 Nov 23;360(9346):1673-81
12457803
Can J Gastroenterol. 2007 Feb;21(2):101-4
17299614
Gastroenterology. 1996 Apr;110(4):1107-19
8613000
Ann Intern Med. 2003 Apr 15;138(8):627-33
12693884
Blood. 2006 May 1;107(9):3455-62
16352812
Blood. 2000 May 1;95(9):2776-9
10779420
Eur J Haematol. 2008 Feb;80(2):168-76
18028431
Haematologica. 2010 Apr;95(4):557-66
19951979
Acta Haematol. 2009;122(2-3):134-9
19907150
Blood. 2007 Jan 1;109(1):362-4
16960153
Leuk Res. 2010 Sep;34(9):1143-50
20451251
Stat Med. 1998 May 30;17(10):1103-20
9618772
Haematologica. 2006 Jul;91(7):873-80
16818273
Blood. 2004 Apr 15;103(8):2914-9
15070663
N Engl J Med. 2008 Jan 17;358(3):221-30
18199861
Mayo Clin Proc. 2004 Mar;79(3):309-13
15008603
Am J Hematol. 2007 Dec;82(12 Suppl):1142-6
17968974
Transl Res. 2008 Jul;152(1):3-10
18593631
Br J Haematol. 2003 Dec;123(5):952-3
14632789
Stat Med. 2008 Jun 15;27(13):2420-39
18344187